Understanding Drug Reactions to Vancomycin
Treatments studied
Part of Immune system & allergy clinical trials.
This research study tests a new antibiotic called vancomycin to understand how the body reacts to it and identify early warning signs. If you qualify, you'll help researchers learn more about sudden allergic-like reactions that aren't traditional allergies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 or older
- Healthy kidney function (normal creatinine level)
- Never received vancomycin before in any form
- No history of allergic reactions to vancomycin or similar antibiotics
- Able to speak and read English at an 8th grade level for safety communication
- Willing to use effective birth control if you can become pregnant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at giving vancomycin continuously in the ICU or orthopedics for the first time, to see if the dosing is done correctly. If you’re an adult receiving this treatment, the trial may help improve how safely and accurately vancomycin is managed.
This trial tests a different way of giving vancomycin to children with sepsis to reduce the risk of kidney injury. It compares standard dosing to an approach that adjusts dose based on how the kidneys are working.
This trial compares two common antibiotic combinations to see which one is less likely to cause kidney injury in hospitalized patients. You may be eligible if you need treatment with vancomycin plus either piperacillin-tazobactam or cefepime.
This Phase 3 study tests whether melatonin can help protect the kidneys in people who are starting or continuing vancomycin, an antibiotic that can sometimes affect kidney function. If you qualify, you would take melatonin as an added prevention step while you’re on vancomycin.
This trial compares two ways of dosing vancomycin (an antibiotic) for serious MRSA infections by using different blood test targets. The goal is to see if the newer approach works at least as well as the standard one, while keeping patients safe.
This Phase 1 study tests whether the antibiotic vancomycin can be given safely to people with newly diagnosed multiple sclerosis (or related early stages). It mainly focuses on safety and side effects, and whether the approach is feasible for this group.
Hear when a new Hypersensitivity Reactions trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.